Medicare Alzheimer's Drug Uptake Lags; Estrogen Patch Shortages Persist
Recent reports highlight significant developments in pharmaceutical accessibility and usage within the United States. Medicare beneficiaries are utilizing newly approved Alzheimer’s medications, specifically Leqembi and Kisunla, at rates far below federal expectations. Consequently, Medicare has revised its financial forecasts, predicting minimal spending on these drugs in 2026 and 2027, a stark contrast to earlier projections of billions in annual costs. This muted uptake is attributed to administration challenges, such as the need for intravenous delivery and extensive imaging, a limited eligible patient population, and concerns regarding severe side effects like brain bleeding versus modest benefits. Simultaneously, patients and physicians are facing difficulties obtaining specific doses of estrogen patches. Despite the American Society of Health-System Pharmacists listing fourteen brands or dosages as being in shortage since January, the FDA has not officially recognized this scarcity. This supply issue coincides with a surge in hormone replacement therapy popularity following the removal of black box warnings late last year. These trends underscore ongoing complexities in drug distribution, regulatory oversight, and patient access to critical treatments in the current healthcare landscape.
Wire timeline
Medicare Alzheimer's Drug Uptake Lags; Estrogen Patch Shortages Persist
Recent reports highlight significant developments in pharmaceutical accessibility and usage within the United States. Medicare beneficiaries are utilizing newly approved Alzheimer’s medications, specifically Leqembi and Kisunla, at rates far below federal expectations. Consequently, Medicare has revised its financial forecasts, predicting minimal spending on these drugs in 2026 and 2027, a stark contrast to earlier projections of billions in annual costs. This muted uptake is attributed to administration challenges, such as the need for intravenous delivery and extensive imaging, a limited eligible patient population, and concerns regarding severe side effects like brain bleeding versus modest benefits. Simultaneously, patients and physicians are facing difficulties obtaining specific doses of estrogen patches. Despite the American Society of Health-System Pharmacists listing fourteen brands or dosages as being in shortage since January, the FDA has not officially recognized this scarcity. This supply issue coincides with a surge in hormone replacement therapy popularity following the removal of black box warnings late last year. These trends underscore ongoing complexities in drug distribution, regulatory oversight, and patient access to critical treatments in the current healthcare landscape.
STAT